MMIRF (MedMira) Moat Score: 3/10 (As of Jun. 28, 2026)


What is MedMira Moat Score?

MedMira MMIRF +302.48% Moat Score is 3 as of Jun. 28, 2026. The stock has 6 warning signs investors should review. Among 1,402 Biotechnology companies, MedMira ranks better than 75.46% on this metric.

MedMira has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

MedMira has No Moat: MedMira Inc has limited market leadership and lacks significant customer switching costs or intellectual property. The company does not exhibit strong brand strength or durable cost advantages, resulting in very weak or transient competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes MedMira might have No Moat - Very weak/transient advantages.

MedMira  (OTCPK:MMIRF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

MedMira Moat Score Related Terms

MMIRF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, MedMira's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MedMira Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Moat Score distribution charts can be found below:

* The bar in red indicates where MedMira's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
MedMira (MMIRF) has a Moat Score of 3 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, MedMira ranks #344 out of 1402 companies in the Biotechnology industry, placing it in the top 24.5%.
Is MedMira's Moat Score too high?
MedMira's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. MedMira's value of 3 is 50% above this industry median. Based on the distribution chart, MedMira ranks #344 out of 1402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does MedMira's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MedMira ranks #344 out of 1402 companies for Moat Score. This places MedMira in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. MedMira's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedMira's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedMira's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedMira stock overvalued right now?
MedMira (MMIRF) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For MedMira (MMIRF), the current Moat Score is 3 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MedMira Business Description

Other Exchanges MIR:Canada
Address 155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company engaged in the research, development, and manufacturing of rapid diagnostics and technologies. The company operates in one reportable operating segment, rapid diagnostic products and services. Its product line includes HIV, COVID-19, syphilis, Multiplex, Miriad RVF Toolkit, and H. pylori. The company generates revenue from North America, Europe, and other regions, with the majority generated from North America.